Purchase Order FA864924P0508
- Not listed
- Gelsana Therapeutics Inc. has been awarded a $74,950 firm fixed price purchase order from the Department of the Air Force Materiel Command Research Laboratory. This contract is part of the Small Business Innovation Research Program Phase I and has a total small business set aside designation. Under the award, Gelsana Therapeutics will conduct research to explore novel zwitterionic hydrogels for improved healing of burns, blast wounds, and chronic wounds, as described in the original SBIR Program...
- The U.S. Air Force Research Laboratory awarded an $1.8M Small Business Technology Transfer (STTR) Phase II contract to Matregenix Inc., a minority-owned small disadvantaged business based in Mission Viejo, California, for development of DERMASPIN, a handheld device designed for contactless application of an antibacterial nanofiber matrix to facilitate rapid wound healing in point-of-care settings. This contract, designated as a Total Small Business set-aside and structured as a firm...
- The U.S. Department of Defense's Defense Health Agency awarded a $1,986,378 Definitive Contract to Synedgen, Inc., a small business prime contractor, to conduct Phase II Small Business Innovation Research (SBIR) efforts for the development of technologies to control scar formation after burn injuries. The contract is designated as a Total Small Business set-aside and has an ultimate completion date of April 1, 2023. Synedgen, a for-profit manufacturer with expertise in regenerative medicine...
- This is a $2,994,281.25 Firm Fixed Price contract awarded by the Defense Health Agency (DHA) to Paranano Wound Care LLC, a small business, under the SBIR (Small Business Innovation Research) program. The contract is for Phase II of a project titled "The BIOZ Smart Bandage Empowering Priority Response to Pathogen Invasion in Wounds" and has an ultimate completion date of July 11, 2027. The contract is focused on medical research and development related to wound care and pathogen...
- <p>This is a $249,726.25 firm fixed-price purchase order awarded by the Defense Health Agency (DHA) to Memsel Inc., a small disadvantaged business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for the development of an "Advanced Hydrogel-Based Drug Delivery System for Enhanced Neuroprotection in Traumatic Brain Injuries" and has a period of performance through May 6, 2025. The contract was set aside for small businesses.</p>
- The Department of the Air Force Materiel Command Research Laboratory awarded a $109,921 firm fixed price Small Business Innovation Research Phase I contract to Matregenix Inc. to develop a handheld device for contactless application of an antibacterial nanofiber matrix to rapidly heal wounds at the point-of-care. The total small business set-aside contract has a period of performance through March 2024. Matregenix Inc. is a minority-owned, self-certified small disadvantaged manufacturer...
- Gelsight, Inc., a small business based in Waltham, Massachusetts, was awarded a $2.0 million Phase II Small Business Innovation Research (SBIR) contract by the Air Force Research Laboratory for the development of high-resolution digital tactile sensors designed to streamline maintenance workflows. This sequential Phase II award, issued on June 20, 2025, is designated as a total small business set-aside and carries a firm fixed-price structure with an ultimate completion date of April 1, 2027....
- The Department of the Army Medical Command awarded a $549,725 firm fixed price Small Business Innovation Research Program Phase III follow-on medical research and development contract to Synedgen, Inc. for the development of technologies that control scar formation after burn injuries. As the prime contractor, Synedgen will leverage its expertise in regenerative medicine and wound healing to advance scientific knowledge and technologies aimed at reducing scarring and improving outcomes for...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the Department of the Army Medical Command (MEDCOM) to Memsel Inc., a self-certified small disadvantaged business. The $249,918.26 contract is for the development of a multi-component hydrogel containing stabilized, encapsulated bacteriophages for the treatment of drug-resistant bacterial infections. This SBIR Phase I contract was set aside for small businesses and is part of MEDCOM's broader efforts to identify...
- This federal contract award is for a Small Business Innovation Research (SBIR) Phase I project awarded by the Air Force Research Laboratory (AFRL) to Matregenix Inc., a minority-owned, self-certified small disadvantaged business manufacturer based in Irvine, California. The contract, valued at $74,832, is for the development of a "Streamlined Synthetic Amniotic Membrane for Ocular Penetrating Injuries and Burns: Simplified Logistics, No Special Storage, Extended Shelf Life." This...
The U.S. Air Force Research Laboratory (AFRL) awarded a $1.25 million Phase II contract to Gelsana Therapeutics Inc., a woman-owned small business and HUBZone-certified firm, to develop novel zwitterionic hydrogels for enhanced wound healing in combat-related burn injuries. The contract, awarded on March 7, 2024, with completion targeted for October 2026, represents a firm fixed-price purchase order under the total small business set-aside program. This award follows Gelsana's Phase I SBIR contract (valued at $74,950 and awarded in May 2023) that explored zwitterionic hydrogel applications for burns, blast wounds, and chronic wounds, demonstrating the company's validated progress in this specialized technology domain. Gelsana Therapeutics specializes in advanced biomaterial development with a core focus on creating controlled-release hydrogel systems that reduce inflammation and accelerate wound healing. The company's technical approach leverages zwitterionic chemistry to address critical medical needs in military healthcare contexts. Beyond this AFRL contract, Gelsana has expanded its therapeutic applications through parallel National Institute of Diabetes and Digestive and Kidney Diseases grants supporting diabetic wound healing solutions, including Provasliex Gel, a zwitterionic hydrogel designed for controlled platelet-derived growth factor delivery in diabetic foot ulcer management. This diversified portfolio underscores the company's commitment to translating military-relevant wound healing innovations into broader civilian healthcare applications.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00004 | Supplemental Agreement for work within scope | $0 | 12/2/25 | |
| P00003 | Supplemental Agreement for work within scope | $0 | 6/3/25 | |
| P00002 | Supplemental Agreement for work within scope | $0 | 3/19/25 | |
| P00001 | Supplemental Agreement for work within scope | $0 | 1/29/25 | |
| Not listed | Not listed | $1.2m | 3/7/24 |